WordNet

a complex consisting of an organic base in association with hydrogen chloride

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 変形性関節症の初回薬物療法 initial pharmacologic therapy of osteoarthritis
2. 過敏性腸症候群に対するアロセトロン塩酸塩（Lotronex） alosetron hydrochloride lotronex for irritable bowel syndrome
3. QT短縮症候群 short qt syndrome
4. クリンダマイシン：概要 clindamycin an overview
5. 成人における急性咽頭炎の対症療法 symptomatic treatment of acute pharyngitis in adults

English Journal

Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation.

Harayama N1, Nihei SI, Nagata K, Isa Y, Goto K, Aibara K, Kamochi M, Sata T.Author information 1Critical Care Medicine, University Hospital, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan, nobuya@med.uoeh-u.ac.jp.AbstractPURPOSE: Nifekalant is a pure potassium channel blocker that has been used to treat ventricular tachyarrhythmias since 1999 in Japan. Intravenous amiodarone was approved later than nifekalant in Japan, and it is still unclear which of the two agents is superior. The aim of this study was to compare the efficacy of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest caused by shock-resistant ventricular fibrillation.
Journal of anesthesia.J Anesth.2014 Jan 5. [Epub ahead of print]
PURPOSE: Nifekalant is a pure potassium channel blocker that has been used to treat ventricular tachyarrhythmias since 1999 in Japan. Intravenous amiodarone was approved later than nifekalant in Japan, and it is still unclear which of the two agents is superior. The aim of this study was to compare
PMID 24389941

Effects of pH on nifekalant-induced electrophysiological change assessed in the Langendorff heart model of guinea pigs.

Kazusa K1, Nakamura Y, Watanabe Y, Ando K, Sugiyama A.Author information 1Department of Pharmacology, Faculty of Medicine, Toho University, Japan.AbstractSince information regarding the effects of pH on the extent of nifekalant-induced repolarization delay and torsades de pointes remains limited, we assessed it with a Langendorff heart model of guinea pigs. First, we investigated the effects of pH change from 7.4 to 6.4 on the bipolar electrogram simulating surface lead II ECG, monophasic action potential (MAP), effective refractory period (ERP), and terminal repolarization period (TRP) and found that acidic condition transiently enhanced the ventricular repolarization. Next, we investigated the effects of pH change from 6.4 to 7.4 in the presence of nifekalant (10 μM) on the ECG, MAP, ERP, TRP, and short-term variability (STV) of MAP90 and found that the normalization of pH prolonged the MAP90 and ERP while the TRP remained unchanged, suggesting the increase in electrical vulnerability of the ventricle. Meanwhile, the STV of MAP90 was the largest at pH 6.4 in the presence of nifekalant, indicating the increase in temporal dispersion of repolarization, which gradually decreased with the return of pH to 7.4.Thus, a recovery period from acidosis might be more dangerous than during the acidosis, because electrical vulnerability may significantly increase for this period while temporal dispersion of repolarization remained increased.
Journal of pharmacological sciences.J Pharmacol Sci.2014;124(2):153-9. Epub 2014 Jan 23.
Since information regarding the effects of pH on the extent of nifekalant-induced repolarization delay and torsades de pointes remains limited, we assessed it with a Langendorff heart model of guinea pigs. First, we investigated the effects of pH change from 7.4 to 6.4 on the bipolar electrogram sim
PMID 24451996

The application of an LC-MS/MS method in a pharmacokinetic study for the determination of the concentration of nifekalant in human plasma.

Zhang M1, Shi G, Sui Y, An Y, Yan M, Tang Y.Author information 1Department of Pharmacy, General Hospital of Shenyang Military Area Command, No 83, Wenhua Road, Shenhe District, Shenyang, 110840, China.AbstractIn the present study, a simple, rapid, and accurate liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of the concentration of Nifekalant in human plasma was developed and validated. The analyte and the internal standard were extracted from human plasma using dichloromethane and analyzed using an ultra-fast liquid chromatographer (UFLC) coupled to an electrospray ionization (ESI) tandem mass spectrometer in the positive mode. The chromatographic analysis was performed isocratically on an Inertsil ODS-SP column (150mm×4.6mm I.D., 5μm). The mobile phase was a mixture of 15% 10mM aqueous ammonium formate and 85% methanol (the pH was adjusted to 3.5 with formic acid) at a flow rate of 0.8mL/min with a split ratio of 1:1 to the ionization source. The lower limit of quantification (LLOQ) was 5.05ng/mL, and a linear calibration curve was obtained over the concentration range of 5.05 to 3030ng/mL. The intra-day and inter-day assay variations were less than 9.06%, and the accuracy values (relative error) were in the range of -10.95% to 2.27%. The essential pharmacokinetic parameters of the intravenously injection of Nifekalant were found to be the following: t1/2=1.26±0.16h,Cmax=1.943±0.411mg/L, and AUC0-12h=4.600±0.756mg/L·h.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.J Chromatogr B Analyt Technol Biomed Life Sci.2013 Nov 1;938:105-10. doi: 10.1016/j.jchromb.2013.09.003. Epub 2013 Sep 7.
In the present study, a simple, rapid, and accurate liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of the concentration of Nifekalant in human plasma was developed and validated. The analyte and the internal standard were extracted from human plasma using dich
PMID 24076524

Japanese Journal

Report From J-PULSE Multicenter Registry of Patients With Shock-Resistant Out-of-Hospital Cardiac Arrest Treated With Nifekalant Hydrochloride

YASUDA Satoshi,SAWANO Hirotaka,HAZUI Hiroshi,UKAI Isao,YOKOYAMA Hiroyuki,OHASHI Junko,SASE Kazuhiro,KADA Akiko,NONOGI Hiroshi
Circulation journal : official journal of the Japanese Circulation Society 74(11), 2308-2313, 2010-10-25
… Background: Nifekalant hydrochloride (NIF) is an intravenous class-III antiarrhythmic agent that purely blocks the K+-channel without inhibiting β-adrenergic receptors. …
NAID 10026972612